GICS Sector : Healthcare
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments.It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning.The company is based in Boston, Massachusetts. Show Full description
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game
Jun -18
HASHICORP INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HashiCorp Inc. - HCP
Jun -14
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger and Expiring Tender Offer - AKLI and CALT
Jun -06
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, SGE on Behalf of Shareholders
Jun -06
STERICYCLE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Stericycle, Inc. - SRCL
Jun -05
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, WIRE on Behalf of Shareholders
Jun -05
PRESSING INVESTIGATION: The M&A Class Action Firm Investigates Merger and Imminent Vote on June 18, 2024, of HomeStreet, Inc. - HMST
Jun -05
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. - AKLI
Jun -04
Akili's Digital Medicine Platform growth is driven by increasing adoption of digital therapeutics, rising demand for personalized medicine, and growing awareness of mental health treatment. The platform's FDA clearance, strong clinical trial results, and partnerships with leading healthcare providers also contribute to its 23.18% growth.
A prescription-only, video game-based treatment for attention deficit hyperactivity disorder (ADHD) in children.
A digital therapeutic platform that uses sensory-based treatments to help individuals with autism spectrum disorder (ASD) and other neurodevelopmental disorders.
A digital therapeutic platform that uses cognitive-behavioral therapy (CBT) and other evidence-based techniques to help individuals manage anxiety disorders.
Akili, Inc. faces moderate threat from substitutes, as there are alternative digital therapeutics available in the market, but they are not as effective as Akili's products.
Akili, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are highly specialized, making it difficult for customers to switch to alternative products.
Akili, Inc. has a strong supply chain management system in place, which reduces the bargaining power of suppliers. The company also has multiple suppliers for each component, which further reduces the bargaining power of individual suppliers.
The digital therapeutics industry is rapidly growing, and new entrants are attracted to the market. Akili, Inc. faces a high threat from new entrants, as they can easily replicate the company's products and services.
The digital therapeutics industry is highly competitive, and Akili, Inc. faces intense rivalry from established players. The company needs to continuously innovate and improve its products to maintain its market share.
| Value | |
|---|---|
| Debt Weight | 19.03% |
| Debt Cost | 12.45% |
| Equity Weight | 80.97% |
| Equity Cost | 12.45% |
| WACC | 12.45% |
| Leverage | 23.50% |
Value: 8.3
Growth: 2.9
Quality: 3.8
Yield: 0.0
Momentum: 9.5
Volatility: 3.3
1-Year Total Return ->
Value: 4.4
Growth: 3.0
Quality: 4.9
Yield: 0.0
Momentum: 8.0
Volatility: 5.3
1-Year Total Return ->
Value: 9.0
Growth: 3.3
Quality: 4.1
Yield: 0.0
Momentum: 6.0
Volatility: 0.7
1-Year Total Return ->
Value: 10.0
Growth: 3.2
Quality: 3.6
Yield: 0.0
Momentum: 6.0
Volatility: 0.0
1-Year Total Return ->
Value: 9.8
Growth: 3.9
Quality: 3.9
Yield: 0.0
Momentum: 0.5
Volatility: 2.0
1-Year Total Return ->
Value: 8.0
Growth: 0.6
Quality: 3.9
Yield: 0.0
Momentum: 6.0
Volatility: 0.0
1-Year Total Return ->